Opinion Video December 24, 2024 Key Takeaways Development of therapies that halt or reverse IPF and PAH progression is a significant unmet need. Improved diagnostic tools are essential for earlier detection and intervention in IPF and PAH. Personalized treatment approaches […]
Unmet Needs in IPF- and ILD-Related Pulmonary Hypertension and Emerging Therapy for IPF Read More »
Opinion Video December 17, 2024 Key Takeaways Development of therapies that halt or reverse IPF and PAH progression is a significant unmet need. Improved diagnostic tools are essential for earlier detection and intervention in IPF and PAH. Personalized treatment approaches
Key Insights on the Use of Inhaled Treprostinil in Treating CTD-PAH Read More »
Opinion Video December 10, 2024 Key Takeaways Current IPF cough treatments are often inadequate, highlighting the need for improved therapeutic strategies and a deeper understanding of underlying mechanisms. The study identifies potential pathways for novel interventions, which could significantly enhance
Insights on Managing Cough Symptoms in Patients With IPF Read More »
Opinion Video December 3, 2024 Key Takeaways The study focused on assessing oral nalbuphine extended release for cough relief in idiopathic pulmonary fibrosis patients. A randomized, double-blind, placebo-controlled trial design was employed to ensure robust and unbiased results. Nalbuphine treatment
Evaluating Cough Relief With Oral Nalbuphine in Patients With IPF Read More »
Opinion Video November 26, 2024 Key Takeaways Development of therapies that halt or reverse IPF and PAH progression is a significant unmet need. Improved diagnostic tools are essential for earlier detection and intervention in IPF and PAH. Personalized treatment approaches
Implications of IPF Survival Data for Clinical Practice and Early Intervention Read More »
Opinion Video November 19, 2024 Key Takeaways Development of therapies that halt or reverse IPF and PAH progression is a significant unmet need. Improved diagnostic tools are essential for earlier detection and intervention in IPF and PAH. Personalized treatment approaches
Findings From the IPF-PRO Registry Read More »
Coming into CHEST 2024, Steven Nathan, MD, discusses how the largest unmet needs in the treatment and management of IPF and PAH include improving early diagnosis, addressing symptom management (particularly chronic cough), and developing more effective, accessible therapies to enhance
CHEST 2024: Updates in IPF and PAH Care Read More »
Abstract Idiopathic pulmonary fibrosis (IPF) is characterized by a progressive decline in lung function, worsening quality of life, and high mortality. However, the rate and pattern of progression of IPF are variable. Real-world studies, which include a broader population of
Real-World Data on the Course of Idiopathic Pulmonary Fibrosis Read More »
